Multiple Sclerosis Community
9.12k Members
382218 tn?1341185087

Study Shows Teva's Copaxone Repairs Tissue In Multiple Sclerosis

Study Shows Teva's Copaxone Repairs Tissue In Multiple Sclerosis

(RTTNews.com) - Teva Pharmaceutical Industries Ltd. (TEVA) Tuesday said a new imaging technique found evidence of tissue repair in relapsing-remitting multiple sclerosis patients treated with Copaxone.

Copaxone is indicated to reduce the frequency of relapses in relapsing-remitting multiple sclerosis or RRMS, including patients who have experienced a first clinical episode and have MRI features consistent with multiple sclerosis.

The 12-month magnetic resonance imaging or MRI study with a non-conventional MRI technique known as Magnetization transfer ratio or MTR, was used to investigate abnormalities in brain structures.

The study examined 40 RRMS Copaxone naive patients between the ages of 18-65 years with disease duration ranging from 6 months to 30 years. All patients had to have one or more contrast-enhancing lesions or CELs. At baseline, the patients presented 115 CELs.

After 12 months of treatment, the number of CELs decreased to 21. The highest MTR increases were observed among hypointense CELs that became isointense (29 percent) and hypointense CELs that remained hypointense (10 percent).

Robert Zivadinov, lead study author, said," These data indicate that treatment with COPAXONE resulted in a measurable amount of tissue repair in study patients."

The study of "Magnetization transfer imaging of acute black holes in patients on glatiramer acetate," was a Phase IV, open-label, single-blinded, post-marketing MRI observational study.

Teva said the results highlight that the MTR technique may be a useful tool to monitor lesion evolution and MS disease progression in future studies.

Copaxone (glatiramer acetate injection) is now approved in more than 50 countries worldwide, including the United States, Russia, Canada, Mexico, Australia, Israel, and all European countries.

TEVA is currently trading at $42.64, up $2.28 or 5.65%, on the Nasdaq. Over the past year, the stock traded in a range of $35.00 - $57.08

1 Responses
1453990 tn?1329235026
Only 40 people in a single blinded open label MRI study,  Even though I am a Copaxone user and consider c "good news," I'd like to see a larger better designed study.  

I have mentioned previously that MT-MRI can see damage up to two years before T2 lesions are present so I'm not surprised that this technique could be used.

Have an Answer?
Top Neurology Answerers
987762 tn?1331031553
5265383 tn?1483811956
1756321 tn?1547098925
Queensland, Australia
1780921 tn?1499305393
Queen Creek, AZ
Learn About Top Answerers
Didn't find the answer you were looking for?
Ask a question
Popular Resources
Find out how beta-blocker eye drops show promising results for acute migraine relief.
In this special Missouri Medicine report, doctors examine advances in diagnosis and treatment of this devastating and costly neurodegenerative disease.
Here are 12 simple – and fun! – ways to boost your brainpower.
Discover some of the causes of dizziness and how to treat it.
Discover the common causes of headaches and how to treat headache pain.
Two of the largest studies on Alzheimer’s have yielded new clues about the disease